Search
Fluocortolone
go.drugbank.com/drugs/DB08971ApprovedWithdrawnFluocortolone is a glucocorticoid with anti-inflammatory activity used topically for various skin disorders.
Mixtures: ULTRALAN POMAT, 10 GR, ULTRALAN POMAT, 20 GRCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersRitonavir
go.drugbank.com/drugs/DB00503ApprovedInvestigationalAmerican Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for … Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors
Mixtures: LOPIMUNE ® + RITONAVIR 10 MG - PELLETS EN CÁPSULAS ORALES, ALUVIA (100 MG/25 MG)Categories: Antivirals used in combination for the treatment of HIV infections, Cytochrome P-450 SubstratesMepivacaine
go.drugbank.com/drugs/DB00961ApprovedInvestigationalVet approvedIt is indicated for infiltration, nerve block, and epidural anesthesia. Mepivacaine is effective topically only in large doses and therefore should not be used by this route.
Mixtures: MEPISEAL-E, Scandonest 2% LSynonyms: N-(2,6-Dimethylphenyl)-1-methyl-2-piperidinecarboxamide, N-(2,6-Dimethylphenyl)-1-methylpiperidine-2-carboxamideUrea
go.drugbank.com/drugs/DB03904ApprovedInvestigationalIt is the principal end product of protein catabolism and constitutes about one half of the total urinary solids. … A compound formed in the liver from ammonia produced by the deamination of amino acids.
Mixtures: HYDROCORTISONE 1% ET UREA 5% CREAM, ÜRESAL FORTE %10 + %10 MERHEM (50 G)Products: UBIT TABLET 100 MG, NUTRAPLUS KREM %10, 100 GDocetaxel
go.drugbank.com/drugs/DB01248ApprovedInvestigational[A259676,L46466] Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiometric ratio, allowing it to prevent cell division and promote to cell death. … [L46466] Docetaxel was approved by the FDA in 1996 and is available in solution for injection for intravenous or parenteral administration.[A259676]
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsSynonyms: N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol, N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxelGalcanezumab
go.drugbank.com/drugs/DB14042ApprovedInvestigational[L42060] It is unknown if galcanezumab has an effect on pregnancy outcomes. A pregnancy exposure registry has been established to evaluate the safety of this drug in pregnant women.[L42060] … [A33112] Galcanezumab was approved by the FDA in September 2018, and is indicated for the preventive treatment of migraine and the treatment of episodic cluster headache.
Products: EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100 MG/ML, EMGALİTY 120 MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 2 ADETSelegiline
go.drugbank.com/drugs/DB01037ApprovedInvestigationalVet approvedIt is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. … It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl.
Categories: Compounds used in a research, industrial, or household setting, Cytochrome P-450 SubstratesProducts: SELEGILINA EG, MOVERDIN 5 MG TABLET, 100 ADETPudexacianinium
go.drugbank.com/drugs/DB19161InvestigationalPudexacianinium is under investigation in clinical trial NCT05754333 (A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery).
Synonyms: )ETHYLIDENE)-2-METHOXYCYCLOHEX-1-EN-1-YL)ETHEN-1-Y, )-1,1-dimethyl-1h-benz(e)indolium ionAlendronic acid
go.drugbank.com/drugs/DB00630ApprovedInvestigationalIt functions by preventing resorption of bone[FDA Label][A959].
Mixtures: BONMEGA 70 MG/2800 IU+1000 MG TEDAVI PAKETI, 4+24 ADET, OSVIPAC 70 MG+1000 MG/880 IU TEDAVI PAKETI, 4+24 ADETSynonyms: 4-amino-1-hydroxybutane-1,1-diphosphonic acid, (4-amino-1-hydroxybutylidene)bisphosphonic acidDalfampridine
go.drugbank.com/drugs/DB06637ApprovedInvestigationalThis is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2E1 SubstratesSynonyms: 4-AP, 4-Aminopyridine